Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: press release (2)

eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 months
press releaseinvestornutraceuticalsvideoscience
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 monthsJuly 22, 2025
Dr. Paul Opgenorth
press releaseinvestornutraceuticalsmedicinescience
eXoZymes selected as core industry partner in $9M NSF-funded initiative to advance modular cell-free biomanufacturingJune 26, 2025
Michael Heltzen & Erum Azeez Khan
heltzenpress releaseinvestorpress clippings
Podcast: eXoZymes highlights scalable biomanufacturing platform and first spinout, NCTx, on 'Grow Everything'May 16, 2025
eXoZymes provides first quarter 2025 and NCTx subsidiary update at 5PM EST today
press releaseinvestor
eXoZymes provides first quarter 2025 and NCTx subsidiary update at 5PM EST todayMay 12, 2025
eXoZymes to host first quarter 2025 and subsidiary NCTx update on Monday May 12, 2025, at 5PM EST
press releaseinvestor
eXoZymes to host first quarter 2025 and subsidiary NCTx update on Monday May 12, 2025, at 5PM ESTMay 7, 2025
eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver health
press releaseinvestornutraceuticalsmedicinescience
eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver healthMay 6, 2025
Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper.
press releaseinvestorvideoscience
GEN Biotechnology cover story: Bringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025
BioClick - an enzyme engineering game-changer
press releaseinvestorscience
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
talentpress releaseinvestorvideo
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025
eXoZymes Provides Fourth Quarter and Full Year 2024 Update
press releaseinvestor
eXoZymes Provides Fourth Quarter and Full Year 2024 UpdateApril 2, 2025
Previous page
Page 2 of 4
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark